Covaxin shows 81 percent efficiency in phase 3 trials
India’s indigenous vaccine ‘Covaxin’ has proved to be up to 81% effective in its Phase III trial against the Corona virus. This information was given by Bharat Biotech, the company that created this vaccine, on Wednesday.
Bharat Biotech reported that Phase III trials of the vaccine were conducted on 25,800 people. The trial conducted with ICMR (Indian Council of Medical Research) is the largest level clinical trial ever conducted in India.
On the other hand, ICMR said that the results of the third phase of the trial were evaluated by an independent data security and monitoring board. In this, it has been found that Covaxin is effective against different age groups and different types of SARS cov-2 present in the country.
COVAXIN has demonstrated an interim vaccine efficacy of 81% in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR: Bharat Biotech pic.twitter.com/jDIka9LIEE
— ANI (@ANI) March 3, 2021
Dr. Balram Bhargava, Director General of ICMR, said, a fully indigenous Covid-19 vaccine (Covaxin) was produced in less than eight months. It shows how ready India is to deal with such challenging situations.
The Union Health Ministry said on Wednesday evening that more than 1.63 crore people have been vaccinated in the country.
PM Modi also given Covaxin dose
The second phase of the vaccination campaign against the corona virus pandemic is going on in India. Two vaccines are being given in the country, one of which is the Covaxin and the other is the ‘Covishield’ developed by Oxford-AstraZeneca.
Earlier on Tuesday, several senior leaders and celebrities, including Prime Minister Narendra Modi, were administered first shot of the vaccine against the coronavirus.
What is Covaxin, how does it work
Covaxin is made by Bharat Biotech in association with ICMR. Dead coronavirus has been used in its manufacture, so that people are not harmed by the vaccine. It produces antibodies in the body against the virus.
Covaxin and Covishield are both two-dose vaccines. A 28-day gap is to be kept between the two doses. This means that if you have taken the first dose of either vaccine today, then you have to take the second dose on the 28th day.
